Pages that link to "Q36667220"

The following pages link to Chromogranin A polymorphisms are associated with hypertensive renal disease. (Q36667220):

Displaying 30 items.

• Association analysis of the ephrin-B2 gene in African-Americans with end-stage renal disease (Q30437420) (← links)
• Global metabolic consequences of the chromogranin A-null model of hypertension: transcriptomic detection, pathway identification, and experimental verification (Q33675339) (← links)
• Essential hypertension and risk of nephropathy: a reappraisal (Q33997784) (← links)
• Genetic basis of nondiabetic end-stage renal disease (Q34018541) (← links)
• Progression of chronic kidney disease: Adrenergic genetic influence on glomerular filtration rate decline in hypertensive nephrosclerosis. (Q34038082) (← links)
• Hypertensive nephropathy: prevention and treatment recommendations (Q34131899) (← links)
• Naturally occurring genetic variants in human chromogranin A (CHGA) associated with hypertension as well as hypertensive renal disease. (Q34435126) (← links)
• Catecholamine Storage Vesicles: Role of Core Protein Genetic Polymorphisms in Hypertension (Q34467436) (← links)
• Target organ damage in African American hypertension: role of APOL1. (Q35658743) (← links)
• Molecular Mechanism for Hypertensive Renal Disease: Differential Regulation of Chromogranin A Expression at 3'-Untranslated Region Polymorphism C+87T by MicroRNA-107 (Q35903118) (← links)
• The regulated secretory pathway and human disease: insights from gene variants and single nucleotide polymorphisms (Q37072233) (← links)
• Adrenergic genetic mechanisms in hypertension and hypertensive kidney disease (Q37089978) (← links)
• MicroRNA-22 and promoter motif polymorphisms at the Chga locus in genetic hypertension: functional and therapeutic implications for gene expression and the pathogenesis of hypertension. (Q37111953) (← links)
• Chromogranin A regulates renal function by triggering Weibel-Palade body exocytosis (Q37259309) (← links)
• Adrenergic beta-1 receptor genetic variation predicts longitudinal rate of GFR decline in hypertensive nephrosclerosis. (Q37467503) (← links)
• Susceptibility genes in common complex kidney disease (Q37616991) (← links)
• Chromogranin A: a novel susceptibility gene for essential hypertension (Q37639931) (← links)
• Chromogranin peptides in brain diseases (Q37870763) (← links)
• Disorders of blood pressure regulation-role of catecholamine biosynthesis, release, and metabolism (Q37954116) (← links)
• Genetics meets epigenetics: Genetic variants that modulate noncoding RNA in cardiovascular diseases (Q38627444) (← links)
• Serum tumor markers in chronic kidney disease: as clinical tool in diagnosis, treatment and prognosis of cancers (Q38747437) (← links)
• Potential applications of catestatin in cardiovascular diseases (Q38896495) (← links)
• Analysis and validation of traits associated with a single nucleotide polymorphism Gly364Ser in catestatin using humanized chromogranin A mouse models (Q41590605) (← links)
• Tumour markers and kidney function: a systematic review. (Q41858828) (← links)
• Catestatin, a chromogranin A-derived peptide, is sympathoinhibitory and attenuates sympathetic barosensitivity and the chemoreflex in rat CVLM. (Q42498258) (← links)
• Common genetic variants in the chromogranin a promoter are associated with renal injury in IgA nephropathy patients with malignant hypertension (Q43180494) (← links)
• Gene polymorphism of vascular endothelial growth factor -1154 G>A is associated with hypertensive nephropathy in a Hispanic population. (Q44562858) (← links)
• Mice overexpressing chromogranin A display hypergranulogenic adrenal glands with attenuated ATP levels contributing to the hypertensive phenotype (Q47640951) (← links)
• Phenylethanolamine N-methyltransferase gene polymorphisms and adverse outcomes in acute kidney injury. (Q55261249) (← links)
• Relation of neuropeptide Y gene expression and genotyping with hypertension in chronic kidney disease (Q92436889) (← links)